Australia's Cyclopharm rises on med-tech clinical guideline win in US

4DMedical

27/01/2026 01:14

** Shares of Cyclopharm CYC.AX advance as much as 15.34% to A$1.015, their biggest intraday pct gain December 1, 2025

** The radiopharmaceutical co notes a key draft U.S. clinical guideline from the country's peak nuclear medicine body, which explicitly names its Technegas lung‑imaging agent as a preferred ventilation option

** Separately, co says its insurer has accepted indemnity over legal proceedings lodged by med tech co 4DMedical 4DX.AX and has assumed conduct of the defence on the firm's behalf

** Proceedings alleged that CYC made false or misleading comments during a webinar in March last year about 4DX's capital‑raising statements

** Over 66,000 shares change hands, 2.3x the 30-day avg

** Stock last year lost 38.2%

 (Reporting by Kumar Tanishk in Bengaluru)

 ((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))